Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Altropane (123I) Dose Evaluation for PD Imaging
NCT05636852Phase 2Terminated
- Sponsor
- GE HealthCare
- Start
- Apr 2023
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of altropane in Parkinson's disease (PD), movement disorders, sponsored by GE HealthCare. Started Apr 2023; status: terminated.
02
Drugs
altropane
03
Conditions
Parkinson's disease (PD)movement disorders
Beyond the preview
Go deeper on NCT05636852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636852.